

Appendix 4E

Full Year Report

30 June 2020

CannPal Animal Therapeutics Limited

ABN 88 612 791 518

Results for announcement to the market

		June 2020	June 2019
Financial Results	Movement	\$	\$
Revenue from ordinary activities	-41%	60,834	103,579
Loss from ordinary activities after tax attributable to members	-15.13%	1,703,571	2,007,288
Net loss for the period attributable to members	-15.13%	1,703,571	2,007,288

Dividends	Amount per Ordinary Security
2020 final dividend	N/A
2019 final dividend	N/A

Net Tangible Asset Backing	June 2020	June 2019
Net tangible asset backing per ordinary security	\$0.02	\$0.03

Earnings Per Share (Basic)	June 2020	June 2019
Earnings per share attributable to the ordinary equity - cents	(1.83)	(2.16)

**CANNPAL ANIMAL THERAPEUTICS LIMITED
PRELIMINARY FINAL REPORT
STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 30 JUNE 2020**

	30 June 2020 \$	30 June 2019 \$
Income		
Research & Development tax refund	654,421	297,300
ATO cash flow boost	50,000	-
Interest income	<u>60,834</u>	<u>103,579</u>
Total income	<u>765,255</u>	<u>400,879</u>
Expenses		
Employee expenses	110,933	107,769
Legal and ASX fees	58,484	52,378
Research & Development	1,774,996	1,558,298
Corporate and Administration costs	422,705	478,151
Share based payments	<u>101,708</u>	<u>211,571</u>
Total expenses	<u>(2,468,826)</u>	<u>(2,408,167)</u>
Loss before income tax	(1,703,571)	(2,007,288)
Income tax benefit/(expense)	<u>-</u>	<u>-</u>
Loss after income tax	<u>(1,703,571)</u>	<u>(2,007,288)</u>
Net loss for the year attributable to members of CannPal Animal Therapeutics Limited	<u>(1,703,571)</u>	<u>(2,007,288)</u>
Other comprehensive income, net of tax	<u>-</u>	<u>-</u>
Total comprehensive loss for the year attributable to the members of CannPal Animal Therapeutics Limited	<u>(1,703,571)</u>	<u>(2,007,288)</u>

**CANNPAL ANIMAL THERAPEUTICS LIMITED
PRELIMINARY FINAL REPORT
STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2020**

	30 June 2020 \$	30 June 2019 \$
ASSETS		
Current assets		
Cash and cash equivalents	1,915,662	3,304,878
Trade and other receivables	<u>30,471</u>	<u>53,513</u>
Total current assets	<u>1,946,133</u>	<u>3,358,391</u>
Total assets	<u>1,946,133</u>	<u>3,358,391</u>
LIABILITIES		
Current liabilities		
Trade and other payables	291,550	110,304
Provisions	<u>42,674</u>	<u>34,315</u>
Total current liabilities	<u>334,224</u>	<u>144,619</u>
Total liabilities	<u>334,224</u>	<u>144,619</u>
Net assets	<u>1,611,909</u>	<u>3,213,772</u>
EQUITY		
Issued capital	6,975,607	6,975,607
Reserves	1,729,727	1,628,019
Accumulated losses	<u>(7,093,425)</u>	<u>(5,389,854)</u>
Total equity	<u>1,611,909</u>	<u>3,213,772</u>

**CANNPAL ANIMAL THERAPEUTICS LIMITED
PRELIMINARY FINAL REPORT
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 30 JUNE 2020**

	30 June 2020 \$	30 June 2019 \$
Cash flows from operating activities		
Payments to suppliers and employees	(2,154,471)	(2,210,241)
Research & Development tax refund	654,421	297,300
ATO cash flow boost	50,000	-
Interest received	<u>60,834</u>	<u>103,580</u>
Net cash outflows from operating activities	<u>(1,389,216)</u>	<u>(1,809,361)</u>
Net increase in cash and cash equivalents	(1,389,216)	(1,809,361)
Cash and cash equivalents at the beginning of the financial year	<u>3,304,878</u>	<u>5,114,239</u>
Cash and cash equivalents at end of year	<u>1,915,662</u>	<u>3,304,878</u>

**CANNPAL ANIMAL THERAPEUTICS LIMITED
PRELIMINARY FINAL REPORT
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 JUNE 2020**

	Issued capital \$	Share based payments reserve \$	Accumulated losses \$	Total \$
Balance at 1 July 2019	6,975,607	1,628,019	(5,389,854)	3,213,772
Total Comprehensive Income				
Loss for the year	-	-	(1,703,571)	(1,703,571)
Total comprehensive loss for the year	-	-	(1,703,571)	(1,703,571)
<i>Transactions with owners in their capacity as owners</i>				
Share based payment	-	101,708	-	101,708
Balance at 30 June 2020	<u>6,975,607</u>	<u>1,729,727</u>	<u>(7,093,425)</u>	<u>1,611,909</u>
Balance at 1 July 2018	6,975,607	1,416,448	(3,382,566)	5,009,489
Total Comprehensive Income				
Loss for the year	-	-	(2,007,288)	(2,007,288)
Total comprehensive loss for the year	-	-	(2,007,288)	(2,007,288)
<i>Transactions with owners in their capacity as owners</i>				
Share based payment	-	211,571	-	211,571
Balance at 30 June 2019	<u>6,975,607</u>	<u>1,628,019</u>	<u>(5,389,854)</u>	<u>3,213,772</u>

**CANNPAL ANIMAL THERAPEUTICS LIMITED
PRELIMINARY FINAL REPORT
FOR THE YEAR ENDED 30 JUNE 2020**

	30 June 2020 Number	30 June 2019 Number
EARNINGS PER SHARE		
Weighted average number of ordinary shares outstanding during the year used in the calculation of basic earnings per share	<u>93,125,000</u>	<u>93,125,000</u>

ISSUED CAPITAL

	30 June 2020 Shares	30 June 2020 \$	30 June 2019 Shares	30 June 2019 \$
Ordinary shares fully paid	<u>93,125,000</u>	<u>6,975,607</u>	<u>93,125,000</u>	<u>6,975,607</u>

Movements in ordinary share capital:

Date	Details	Number of shares	\$
1 July 2019	Opening balance	93,125,000	6,975,607
30 June 2020	Balance	<u>93,125,000</u>	<u>6,975,607</u>

Fully paid ordinary shares carry one vote per share and carry the right to dividends.

CONTINGENT ASSETS & LIABILITIES

The Company has a commitment of US\$45,000 under an agreement for research and development costs. Subject to achieving some conditions in the agreement, there may be further commitment.

There are no other contingent liabilities or contingent assets as at 30 June 2020.

EVENTS AFTER BALANCE SHEET DATE

The impact of the Coronavirus (COVID-19) pandemic is ongoing and while it has no significant impact up to 30 June 2020, it is not practicable to estimate the potential impact, positive or negative, after the reporting date. The situation is rapidly developing and is dependent on measures imposed by the Australian Government and other countries, such as maintaining social distancing requirements, quarantine, travel restrictions and any economic stimulus that may be provided.

The directors are not aware of any other matter or circumstance that has significantly or may significantly affect the operations of the company or the results of those operations, or the state of affairs of the company in subsequent financial years.

Annual meeting

The annual meeting will be held as follows:

Place	To be advised
Date	To be advised
Time	To be advised
Approximate date the annual report will be available	30 September 2020

Compliance Statement

- 1 This report has been prepared in accordance with AASB Standards, other AASB authoritative pronouncements and Urgent Issues Group Consensus Views or other standards acceptable to ASX.

Identify other standards used

- 2 This report, and the accounts upon which the report is based, use the same accounting policies.
- 3 This report does give a true and fair view of the matters disclosed.
- 4 This report is based on accounts which are in the process of being audited.
- 5 The entity has a formally constituted audit committee.

Date: 20 August 2020

Baden M Bowen
Company Secretary